In another study by Van Boxtel et al., 2015 [279], abnormal levels of Gal-3 were detected in 7.3% of breast cancer patients (4 out of 55 patients) after treatment with anthracyclines. This evidence concerns the gene LGALS3 and breast carcinoma.